Sign in
Not yet recruitingPhase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications

Key facts

Who runs it
Cidara Therapeutics Inc.
Where
Germany8 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
400 people, planned
Started
15 Oct 2026
Expected to end
9 Aug 2027
Type of study
Interventional
Record updated
15 October 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Must be 12 years of age or older at the time of signing the informed consent; Additional Inclusion Criteria for Primary Stratum A: A2. Has moderate to severe asthma, as defined by the Global Initiative for Asthma (GINA 2025) Treatment Steps 3-5; Additional Inclusion Criteria for Primary Stratum A: A3. Has existing cardiac disease; specifically: • Congenital heart disease • Congestive heart failure NYHA Class II-IV (Criteria Committee of the New York Heart Association 2025) • Coronary artery disease requiring regular medication and/or follow-up for ischemic heart disease (i.e., participants who, through interventional procedure(s) and/or active medical treatment, have attained an established state of chronic stability of a duration of no less than 6 months) • Hypertension with cardiac complications (NOTE: Hypertension alone without cardiac complications will be excluded). Acceptable cardiac complications of hypertension include, but are not limited to, heart failure, cardiac arrhythmias (eg, atrial fibrillation), ischemic heart disease, coronary artery disease, enlarged left heart, metabolic syndrome, left ventricular hypertrophy, systolic or diastolic myocardial dysfunction, angina, and myocardial infarction
  • Written informed consent and any locally required authorization (eg, Health Insurance Portability and Ac-countability Act [HIPAA] in the US) ob-tained from the participant before per-forming any protocol-related proce-dures, including screening evaluations. For participants under the legal age of consent as defined by local regulations, the parent(s) or legal guardian(s) may be required to give their signed written informed consent and participants may sign an assent form as specified by local law
  • Has negative rapid antigen tests for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prior to dosing at Day 1
  • Weight is ≥ 40 kg at screening
  • Body Mass Index (BMI) is ≥ 18 kg/m2 at screening; Additional Inclusion Criteria for Primary Stratum A: A6. Is ≥ 65 years of age at the time of randomization but does not meet any of criteria A1 through A5, and is otherwise healthy as determined by the Investigator or designee; Additional Inclusion Criteria for Primary Stratum B: B1. Has a solid tumor diagnosis AND has received chemotherapy and/or immunotherapy within 1 year of screening; Additional Inclusion Criteria for Primary Stratum B: B2. Has a diagnosis of a hematologic malignancy within 5 years of screening AND has received any chemotherapy or biologic therapy within 1 year of screening; Additional Inclusion Criteria for Primary Stratum B: B3. Participants who have had a solid organ transplant (SOT) must satisfy all of the following: • Has received a kidney, liver, heart, or lung transplant more than 6 months prior to screening • Is currently receiving at least two immunosuppressive medications
  • In the opinion of the Investigator or designee, must be able to comply with the requirements of the protocol and be able to read, understand, and complete questionnaires in the electronic diary (eDiary), work with smartphones/tablets/computers (if ap-plicable, with assistance by a caregiver, surrogate, or legally authorized repre-sentative), and be willing and able to adhere to the prohibitions and re-strictions specified in this protocol. If an appropriate language version is not available for the eDiary assessments, the participant should not be enrolled; Additional Inclusion Criteria for Primary Stratum B: B4. Participants who have had a hematopoietic stem cell transplant (HSCT) must satisfy at least one of the following: • Has a history of hematopoietic stem cell transplantation (HSCT) (i.e., autologous, allogeneic, bone marrow, peripheral blood stem cell, tandem [peripheral blood and marrow]) within 1 year of screening • Has a history of non-autologous HSCT with graft-versus-host disease (GvHD) requiring active treatment with immunosuppressants (eg, systemic corticosteroids ≥1 mg/kg at screening), regardless of the duration of time since HSCT; Additional Inclusion Criteria for Primary Stratum B: B5. Is receiving immunosuppressive medicines (eg, corticosteroids [ie, at least 20 mg prednisone or equivalent per day], alkylating agents, antimetabolites, transplantrelated immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive [eg, Bruton’s tyrosine kinase inhibitors], tumornecrosis blockers, or other immunosuppressive biologic agents [eg, for rheumatic diseases]); Additional Inclusion Criteria for Primary Stratum B: B6. Has received chimeric antigen receptor-modified T-cell therapy; Additional Inclusion Criteria for Primary Stratum B: B7. Has received B-cell depleting therapies (eg, rituximab, ocrelizumab, ofa-tumumab, alemtuzumab) within the 12 months prior to screening; Additional Inclusion Criteria for Primary Stratum B: B8. Has a diagnosis of any primary immunodeficiency except IgA deficiency; Additional Inclusion Criteria for Primary Stratum B: B9. Has advanced or untreated human immunodeficiency virus (HIV) infection manifested by a CD4 cell count <350/mm3 within 6 months of screening
  • Must be assessed by the Investigator or designee as medically stable and not requiring significant change in mainte-nance therapy and has not been hospi-talized for worsening disease or any significant medical event during the 2 months before screening
  • Female participants must agree to the contraception requirements in pro-tocol section 5.4.2. Definitions related to childbearing potential are provided in protocol section 5.4.1
  • Must agree not to donate blood or blood products from Day 1 until 32 weeks after study intervention administration; Additional Inclusion Criteria for Primary Stratum A: A4. Has insulin-dependent diabetes; Additional Inclusion Criteria for Primary Stratum A: A5. Has moderate renal impairment (Stage 3 Chronic Kidney Disease [CKD], equivalent to an eGFR 30-59 mL/min/1.73m2 as calculated by CKD-EPI equation (Inker 2021) for adults or the CKiD U25 equation (NIDDK 2025) for adolescents) with or without micro-macroproteinuria and within 3 months prior to screening; examples include, but are not limited to, any history of glomerulosclerosis, diabetic nephropathy, lupus nephritis, glomerular nephritis, IgA nephropathy, and Goodpasture syndrome
  • Must be willing to provide verifiable identification, has means to be contacted, and is able to contact the Investigator or designee/study site and communicate reliably during participation in the study; Additional Inclusion Criteria for Primary Stratum A: A1. Has a history of pulmonary disease; specifically: • Chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, graded as follows using the GOLD ABE (GOLD 2025) assessment tool: o Gold Grade 2 (moderate) or Grade 3 (severe) with following exacerbation history, within 1 year of screening - At least 2 moderate exacerbations (i.e., not leading to hospitalization), or - At least 1 exacerbation leading to hospitalization OR o Gold Grade 4 regardless of exacerbation history • Bronchiectasis, cystic fibrosis, interstitial lung disease, pneumoconiosis, or past or active bronchopulmonary dysplasia

Who cannot take part

  • Had major surgery (eg, major cardiac, pulmonary or abdominal operation) within 4 weeks prior to randomization, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the study
  • Receipt within the past 30 days or 5 half-lives (whichever is longer) or anticipated receipt of any drug or other biologic agent (eg, mAbs) administered for the prevention or treatment of influenza
  • Receipt of any formulation of immunoglobulin within 14 days prior to planned study intervention administration
  • Receipt of any experimental drug, vaccine, or biologic agent within the 90 days or 5 halflives (whichever is longer) prior to study intervention administration
  • Has direct involvement in the proposed study or in other studies under the direction of the Investigator or designee, sub-investigators, or at the study site; or is a family member of an individual with such direct involvement; or is an employee of the Sponsor; or was previously enrolled and dosed in a CD388 clinical trial
  • Has previously enrolled in this study (CD388.SQ.3.06)
  • Has been diagnosed with influenza (ie, with medical history [including verbal] of influenza) within the 6 months prior to randomization
  • Has received the current seasonal inactivated influenza vaccine or live attenuated influenza vaccine within the 14 days prior to dosing on Day 1
  • Has an acute (time-limited) or febrile (temperature ≥ 38.0°C [≥ 100.4°F]) illness within 7 days prior to planned dosing on Day 1
  • In the Investigator’s or designee’s judgment, the participant has any condition or circumstance present that significantly increases risk, affects the ability to participate, impairs interpretation of study data, or indicates a likelihood of non-adherence to study requirements
  • Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to zanamivir (following administration of inhaled or intravenous formulations), mAbs (including Fc domains), or any of the components of CD388 or placebo
  • Has a clinically unstable condition including, but not limited to, a psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior, or any other condition for which, in the opinion of the Investigator or designee, may lead to hospitalization or death within the study period and that suggests that study enrollment would not be in the participant’s best interest and/or that could prevent, confound, or limit the protocol-specified assessments
  • Has any history of alcohol or substance abuse, that in the opinion of the Investigator or designee, would adversely impact the conduct of the study
  • Has screening electrocardiogram (ECG) findings of prolonged QT interval corrected using Fridericia’s formula (QTcF) (> 450 msec in males or > 470 msec in females), prolonged PR interval (> 220 msec), second- or third-degree heart block, or other clinically significant dysrhythmias, unless participant has a known cardiac diagnosis responsible for the ECG findings and is in stable condition
  • Has a clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder) or medical history of significant bleeding or bruising following intramuscular or SQ injections or venipuncture
  • Has severe CKD (equivalent to an eGFR < 30 mL/min /1.73m2 as calculated by CKD-EPI equation for adults or the CKiD U25 equation for adolescents), or is receiving hemodialysis
  • Has had close contact (including household contact) with someone with laboratory-confirmed influenza or SARS-CoV-2 or with someone who has been treated with antiviral therapies for influenza or SARS-CoV-2 within the 7 days prior to randomization
  • A female who is pregnant or lactating
  • Current or planned participation in another clinical study in which study intervention is being administered during participation in the current study
  • Has donated ≥ 450 mL of blood product (1 unit) for any reason within 30 days of screening

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the clinical efficacy of CD388 in preventing symptomatic laboratory-confirmed influenza infections compared to placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
15 October 2026